Our study still has some limitations, such as the lack of detection of plasma VEGFB levels in patients with NAFLD, and whether VEGFB has the therapeutic effect of improving or reducing NAFLD liver injury. This evidence concerns the gene VEGFB and metabolic dysfunction-associated steatotic liver disease.